Long-term safety and efficacy of Omnitrope® in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study

被引：0

作者：

D. Ferone

E. Profka

V. Gasco

M. R. Ambrosio

A. Colao

C. Di Somma

E. Puxeddu

G. Arnaldi

C. Pagano

E. Zecchi

A. Pietropoli

P. Beck-Peccoz

机构：

[1] Center of Excellence for Biomedical Research (CEBR),Endocrinology Unit, Department of Internal Medicine and Medical Specialties (DiMI)

[2] IRCCS AOU San Martino-IST,Endocrinology and Metabolic Diseases Unit, Department of Clinical Sciences and Community Health

[3] University of Genova,Endocrinology, Diabetes and Metabolism, Department of Medical Science

[4] Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca’ Granda Ospedale Maggiore Policlinico,Section of Endocrinology and Internal Medicine, Department of Medical Sciences

[5] University of Milano,Department of Clinical Medicine and Surgery

[6] Città della Salute e della Scienza di Torino,Veterinary and Forensic Biotechnological Sciences Department of Medicine Section, Internal Medicine, Endocrine and Metabolic Sciences

[7] University of Torino,Department of Medicine, Internal Medicine 3

[8] University of Ferrara,Endocrinology and Diabetology Unit, Medical Sciences Department

[9] University Federico II of Napoli,undefined

[10] Institute of Diagnostic and Nuclear Research,undefined

[11] Fondazione Istituto di Ricovero e Cura a Carattere Scientifico SDN,undefined

[12] University of Perugia,undefined

[13] Clinica di Endocrinologia e Malattie del Metabolismo,undefined

[14] Ospedali Riuniti di Ancona,undefined

[15] University of Padova,undefined

[16] Sandoz S.p.A.,undefined

[17] Hexal AG,undefined

[18] Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Cà Granda Ospedale Maggiore Policlinico,undefined

来源：

Journal of Endocrinological Investigation | 2017年 / 40卷

关键词：

Growth hormone deficiency; Hypopituitarism; Omnitrope®; Recombinant human growth hormone; Insulin-like growth factor-1; Safety;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：669 / 678

页数：9

共 122 条

[1]

Ho KK(2007)Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia Eur J Endocrinol 157 695-700

[2]

Gupta V(2011)Adult growth hormone deficiency Indian J Endocrinol Metab 15 S197-S202

[3]

Molitch ME(2011)Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 96 1587-1609

[4]

Clemmons DR(2013)Adult growth hormone deficiency—benefits, side effects, and risks of growth hormone replacement Front Endocrinol (Lausanne) 4 64-301

[5]

Malozowski S(2016)One-year GH replacement therapy reduces early cardiac target organ damage (TOD) in adult GHD patients Endocr 2 298-91

[6]

Merriam GR(2010)Assessing the efficacy and safety of Omnitrope Br J. Clin Pharm 3 85-81

[7]

Vance ML(2012)Rationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope Ther Adv Endocrinol Metab 95 74-889

[8]

Reed ML(2010) for the treatment of adult patients with growth hormone deficiency J Clin Endocrinol Metab 165 881-2261

[9]

Merriam GR(2011)Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement Eur J Endocrinol 96 2255-361

[10]

Kargi AY(2011)Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis J Clin Endocrinol Metab 98 352-613

← 1 2 3 4 5 6 7 8 9 10 →